首页 | 本学科首页   官方微博 | 高级检索  
检索        

加味茯苓甘草汤防治慢性常压缺氧性肺动脉高压的实验研究
引用本文:王伯章,陈莉延,洪杰斐,彭勃,宋泽庆,黄泽辉.加味茯苓甘草汤防治慢性常压缺氧性肺动脉高压的实验研究[J].广州中医药大学学报,2002,19(1):27-30.
作者姓名:王伯章  陈莉延  洪杰斐  彭勃  宋泽庆  黄泽辉
作者单位:1. 广东医学院附属医院中医科,广东,湛江,524001
2. 广东医学院附属医院内科,广东,湛江,524001
基金项目:广东省中医药管理局课题(编号:97254)
摘    要:目的:探讨中药复方制剂加味茯苓甘草汤(茯苓、甘草、桂枝、桃仁、苇茎等组成)对慢性肺动脉高压(HPH)的防治作用。方法:常压缺氧法建立HPH大鼠模型,以生理盐水为对照药,设对照组、缺氧组和中药治疗组,灌胃3周,检测平均肺动脉压力(mPAP),观察右心室与左心室加室间隔重量之比mR/(mL mS]、血浆及肺匀浆中磷脂酶A2(PLA2)、血栓素B2(TXB2)、6-酮-前列腺素(6-keto-PGF1α)、超氧化物歧化酶(SOD)及丙二醛(MDA)的变化。结果:①缺氧组大鼠mPAP、mR/(mL mS)、 PLA2、TXB2、MDA含量增加,6-keto-PGF1α、SOD含量下降,与对照组相比有显著性差异(P<0.01);②加味茯苓甘草汤能降低mPAP、mR/(mL mS),与缺氧组相比,前者有显著性差异(P<0.01);③加味茯苓甘草汤能使肺组织中PLA2、6-keto-PGF1α、TXB2、MDA含量降至正常水平,与缺氧组相比差异有显著性(P<0.01或P<0.05);④加味茯苓甘草汤能使血浆中PLA2、6-keto-PGF1α、SOD含量下降,与缺氧组相比差异有显著性(P<0.05或P<0.01),TXB2、MDA含量无明显变化。结论:长期使用加味茯苓甘草汤可有效防治慢性缺氧性肺动脉高压,其机理与抑制PLA2及相关炎性介质,降低自由基的毒性有关。

关 键 词:茯苓甘草汤  防治  慢性常压缺氧性肺动脉高压  实验研究
文章编号:1007-3213(2002)01-0027-04
修稿时间:2001年10月23

Experimental Studies of Modified Fuling Gancao Decoction in Preventing and Treating Chronic Normotensive Hypoxic Pulmonary Hypertension
WANG Bozhang,CHEN Liyan,HONG Jiefei,PENG Bo,SONG Zeqing,HUANG Zehui.Experimental Studies of Modified Fuling Gancao Decoction in Preventing and Treating Chronic Normotensive Hypoxic Pulmonary Hypertension[J].Journal of Guangzhou University of Traditional Chinese Medicine,2002,19(1):27-30.
Authors:WANG Bozhang  CHEN Liyan  HONG Jiefei  PENG Bo  SONG Zeqing  HUANG Zehui
Abstract:Objective] To investigate the preventive and therapeutic effect of Modified Filling Gancao Decoction (MFGD) for chronic normotensive hypoxic pulmonary hypertension. Methods] Twenty - nine rats were allocated to three groups: normal control group (Group A), model group ( Group B) and MFGD group ( Group C). After three -week gastric infusion of normal saline or MFGD, mean pulmonary arterial pressure(MPAP), right ventricle and left ventricle added with interventricular septum weight ratio mR/( mL + mS) ] and the levels of phospholipase A2(PLA2),thromboxane B2 (TXB2), 6- keto - PGF1a, superoxide dismutase (SOD) and malonaldehyde (MDA) in plasma and lung homogenate were measured. Results] MPAP, mR/ (mL+ mS) and the levels of PLA2, TXB2 and MDA increased and 6 - keto - PGF1a and SOD levels decreased in Group B (P<0.01as compared with Group A). In Group C, MPAP, mR/ (mL+mS) and the levels of PLA2 and 6 - keto - PGF1a in plasma and lung homogenate were decreased, TXB2 and MDA in lung homogenate and SOD in plasma were also decreased (P <0.01 or 0.05as compared with Group B). Conclusion ] Long - term medication of MFGD can prevent and treat chronic hypoxic pulmonary hypertension, and its mechanism may be related to the inhibition of PLA2 and associated inflammatory medium and the reduction of the toxicity of free radicals.
Keywords:MODIFIED FULING GANCAO DECOCTION/pharmacology  PULMONARY HYPERTENSION/TCD therapy  FULING GANCAO DECOCTION/therapeutic use  WEIJING DECOCTION/therapeutic use  PHOSPHOLIPASE A  THROMBOXANE B2  DISEASE MODELS  ANIMAL  RATS
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号